NCT07340658 2026-04-02
SIE-3
Rovi Pharmaceuticals Laboratories
Phase 3 Not yet recruiting
Clinical Trials
10 trialsNCT07394946 2026-02-20
NELOPHER
Cancer Care Hospital & Research Centre Foundation, Lahore
Phase 2 Not yet recruiting
NCT07305246 2025-12-26
Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT07101159 2025-08-03
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06223698 2025-04-20
SWE-Switch
Region Örebro County
Phase 3 Not yet recruiting
NCT06810492 2025-03-17
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
Hubei Cancer Hospital
Phase NA Not yet recruiting
NCT06341283 2024-05-10
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
The Affiliated Hospital of Qingdao University
Not yet recruiting
NCT05979220 2023-08-07
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT05131893 2021-11-23
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Not yet recruiting
NCT04137640 2021-07-20
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy
Shengjing Hospital
Phase 4 Not yet recruiting